Clinical Trial Details

USOR 17160

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Pancreatic Cancer
Study Type: Interventional
Phase: III
Study Start Date: 03/01/2019
Study Completion Date: 12/2022

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

 

 

NCT Number

NCT03377491

Principal Investigator(s)

Manish Agarwal, MD

Sponsor(s)

NovoCure Ltd.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female